Cargando…

Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Is Associated with Cervical Stromal Involvement in Endometrial Cancer Patients: A Cross-Sectional Study in South China

Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a significant health issue closely associated with multiple extrahepatic cancers. The association between MAFLD and clinical outcomes of endometrial cancer (EC) remains unknown. Methods: We retrospectively included 725 EC pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Xite, Chen, Chunxia, Jiang, Tingting, Ma, Jincheng, Huang, Lixiang, Huang, Leyi, Lei, Huifang, Tong, Yao, Huang, Guanxiang, Mao, Xiaodan, Sun, Pengming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136854/ https://www.ncbi.nlm.nih.gov/pubmed/37185400 http://dx.doi.org/10.3390/curroncol30040287

Ejemplares similares

ERRα promotes glycolytic metabolism and targets the NLRP3/caspase-1/GSDMD pathway to regulate pyroptosis in endometrial cancer
por: Su, Pingping, et al.
Publicado: (2023)

Peripheral Blood Lymphocyte Subsets as a Risk Predictor of Patients with Endometrioid Endometrial Cancer
por: Su, Pingping, et al.
Publicado: (2022)

Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis
por: Wang, Xiaolin, et al.
Publicado: (2022)

Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD)
por: Subramanian, Pallavi, et al.
Publicado: (2022)

ERRγ, a Novel Biomarker, Associates with Pathoglycemia of Endometrial Cancer to Predict Myometrial Invasion
por: Tong, Yao, et al.
Publicado: (2022)

Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update
por: Barchetta, Ilaria, et al.
Publicado: (2020)

Platelet-to-Lymphocyte Ratio (PLR) as the Prognostic Factor for Recurrence/Residual Disease in HSIL Patients After LEEP
por: Huang, Guanxiang, et al.
Publicado: (2023)

Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
por: Prasoppokakorn, Thaninee, et al.
Publicado: (2021)

Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)—A Condition Associated with Heightened Sympathetic Activation
por: Carnagarin, Revathy, et al.
Publicado: (2021)

Associations between red blood cell count and metabolic dysfunction-associated fatty liver disease(MAFLD)
por: Dai, Xinyi, et al.
Publicado: (2022)

A43 SEX DIFFERENCES IN THE ASSOCIATION OF HIV WITH METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE (MAFLD)
por: Kablawi, D, et al.
Publicado: (2023)

Uncovering Actions of Type 3 Deiodinase in the Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
por: Marschner, Rafael Aguiar, et al.
Publicado: (2023)

Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment
por: Sangro, Paloma, et al.
Publicado: (2023)

ERRα Up-Regulates Invadopodia Formation by Targeting HMGCS1 to Promote Endometrial Cancer Invasion and Metastasis
por: Tang, Shuting, et al.
Publicado: (2023)

FTO Polymorphisms are Associated with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Susceptibility in the Older Chinese Han Population
por: Gu, Zhan, et al.
Publicado: (2020)

Polysaccharides: The Potential Prebiotics for Metabolic Associated Fatty Liver Disease (MAFLD)
por: Guo, Qin, et al.
Publicado: (2023)

Effects of Dietary Nutrients on Fatty Liver Disease Associated With Metabolic Dysfunction (MAFLD): Based on the Intestinal-Hepatic Axis
por: Yao, Nan, et al.
Publicado: (2022)

MAFLD Criteria Guide the Subtyping of Patients with Fatty Liver Disease
por: Huang, Jiaofeng, et al.
Publicado: (2021)

Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy
por: Zhao, Jianan, et al.
Publicado: (2021)

Identification of Hepatic Dendritic Cells in Liver Biopsies in Patients with Metabolic Dysfunction-Associated Fatty Liver Diseas (MAFLD) and Obesity
por: Barranco-Fragoso, Beatriz, et al.
Publicado: (2022)

Impaired Glucagon-Mediated Suppression of VLDL-Triglyceride Secretion in Individuals With Metabolic Dysfunction–Associated Fatty Liver Disease (MAFLD)
por: Heebøll, Sara, et al.
Publicado: (2022)

Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD
por: Chen, Jie, et al.
Publicado: (2023)

PGC-1α and ERRα in patients with endometrial cancer: a translational study for predicting myometrial invasion
por: Chen, LiLi, et al.
Publicado: (2020)

Lead exposure as a causative factor for metabolic associated fatty liver disease (MAFLD) and a lead exposure related nomogram for MAFLD prevalence
por: Yang, Chenyu, et al.
Publicado: (2022)

What the New Definition of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Left Behind: Genetically Acquired Fatty Liver Disease (GAFLD)
por: Bril, Fernando
Publicado: (2021)

Low Red Blood Cell Count as an Early Indicator for Myometrial Invasion in Women with Endometrioid Endometrial Carcinoma with Metabolic Syndrome
por: Tong, Yao, et al.
Publicado: (2020)

Altered Mitochondrial Quality Control in Rats with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Induced by High-Fat Feeding
por: Cioffi, Federica, et al.
Publicado: (2022)

Hepatoprotective Effect of Bee Bread in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Rats: Impact on Oxidative Stress and Inflammation
por: Zakaria, Zaida, et al.
Publicado: (2021)

Influence of Altered Thyroid Hormone Mechanisms in the Progression of Metabolic Dysfunction Associated with Fatty Liver Disease (MAFLD): A Systematic Review
por: Marschner, Rafael Aguiar, et al.
Publicado: (2022)

Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD)
por: Buzova, Diana, et al.
Publicado: (2020)

Curcumin and Biochemical Parameters in Metabolic-Associated Fatty Liver Disease (MAFLD)—A Review
por: Różański, Gracjan, et al.
Publicado: (2021)

Function of the endolysosomal network in cholesterol homeostasis and metabolic-associated fatty liver disease (MAFLD)
por: Vos, Dyonne Y., et al.
Publicado: (2021)

Gastric Bypass Resolves Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Low-BMI Patients: A Prospective Cohort Study
por: Billeter, Adrian T., et al.
Publicado: (2022)

Emerging trends and hotspots in metabolic dysfunction-associated fatty liver disease (MAFLD) research from 2012 to 2021: A bibliometric analysis
por: Liao, Yudi, et al.
Publicado: (2023)

Thwarting Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) with Common Bean: Dose- and Sex-Dependent Protection against Hepatic Steatosis
por: Lutsiv, Tymofiy, et al.
Publicado: (2023)

Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver
por: Kaya, Eda, et al.
Publicado: (2022)

The Asia Pacific Pediatric Association (APPA) position statement on the MAFLD definition of fatty liver disease
por: Memon, Iqbal A., et al.
Publicado: (2023)

Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota
por: Drożdż, Karolina, et al.
Publicado: (2021)

The Diagnostic and Prognostic Value of the Triglyceride-Glucose Index in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): A Systematic Review and Meta-Analysis
por: Wang, Jing, et al.
Publicado: (2022)

Adipose tissue dysfunction and MAFLD in obesity on the scene of COVID-19
por: Cordeiro, Adryana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_39102j50logr7tvgvmr65co1po